17129-06-5

Basic information

• Product Name: 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one
• Synonyms: 4-ETHOXY-1,1,1-TRIFLUORO-3-BUTEN-2-ONE, TECH.;4-ethoxy-1,1,1-trifluoro-3-buten-2-on;(3E)-4-Ethoxy-1,1,1-trifluorobut-3-en-2-one;4-Ethoxy-1,1,1-trifluoro-3-buten-2-one, 94%, stab.;(E)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one;4-Ethoxy-1,1,1-Trifluoro-3-Buten-2-One, Stab.;2-ethoxyvinyltrifluoroMethylketone;(2-Ethoxyvinyl) trifluoromethyl ketone, 1-Ethoxy-3-oxo-4,4,4-trifluorobut-1-ene
• CAS NO: 17129-06-5
• Molecular Formula: C₆H₇F₃O₂
• Molecular Weight: 168.11
• EINECS: 1312995-182-4
• Product Categories: Alcohol& Phenol& Ethers;C3 to C6;Carbonyl Compounds;Ketones
• Mol File: 17129-06-5.mol
• Article Data: 58

Chemical Properties

• Melting Point: -30℃
• Boiling Point: 51-53 °C12 mm Hg(lit.)
• Flash Point: 125 °F
• Appearance: Colorless to yellow/Liquid
• Density: 1.18 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00541mmHg at 25°C
• Refractive Index: n20/D 1.406(lit.)
• Storage Temp.: 2-8°C
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one(17129-06-5)
• EPA Substance Registry System: 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one(17129-06-5)

Safety Data

• Hazard Codes: Xn,F
• Statements: 10-40
• Safety Statements: 16-36-36/37
• RIDADR: UN 1224 3/PG 3
• WGK Germany: 3
• HazardClass: 3
• PackingGroup: III
• Hazardous Substances Data: 17129-06-5(Hazardous Substances Data)

Usage

Description

4-Ethoxy-1,1,1-trifluoro-3-buten-2-one is a light yellow liquid that exhibits unique reactivity with various reagents, such as phenylmagnesium bromide and organozinc compounds, leading to different substitution and addition products. It is also capable of undergoing [4+2] cycloaddition reactions with triethyl phosphite, and it can react with amino groups to form N-protected amino acids, which are valuable for peptide synthesis.

Uses

Used in Chemical Synthesis:
4-Ethoxy-1,1,1-trifluoro-3-buten-2-one is used as a synthetic intermediate for the production of various organic compounds. It is particularly useful for the synthesis of 4-dialkylamino-1,1,1-trifluorobut-3-ene-2-ones and β-alkylor dialkylamino substituted enones bearing a CF3 group, which are important building blocks in the development of pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one is used as a key component in the synthesis of complex molecular structures with potential therapeutic applications. Its ability to form N-protected amino acids makes it a valuable asset in the development of new drugs and drug candidates.
Used in Material Science:
4-Ethoxy-1,1,1-trifluoro-3-buten-2-one may also find applications in material science, particularly in the development of novel materials with specific properties, such as enhanced stability or reactivity, due to the presence of the trifluoromethyl group.
Used in Research and Development:
In the field of research and development, 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one serves as a versatile compound for exploring new reaction pathways and understanding the fundamental chemistry of organofluorine compounds. Its unique reactivity with various reagents makes it an attractive candidate for studying reaction mechanisms and developing new synthetic methodologies.

InChI:InChI=1/C8H7BrFNO/c1-11-8(12)6-4-5(10)2-3-7(6)9/h2-4H,1H3,(H,11,12)

Upstream product

• 109-92-2 ethyl vinyl ether 
• 354-32-5 trifluoracetyl chloride 
• 109-93-3 1,1'-oxybisethene 
• 421-50-1 1,1,1-trifluoro-2-propanone 
• 109-94-4 formic acid ethyl ester 
• 76-05-1 trifluoroacetic acid 
• 122-51-0 orthoformic acid triethyl ester 
• 354-34-7 trifluoroacetyl fluoride 
• 400-36-2 trifluoroacetylacetic acid 
• 407-25-0 trifluoroacetic anhydride 
• 1095142-49-6 4-chloro-4-ethoxy-1,1,1-trifluoro-3-butan-2-one 
• 17128-99-3 2-(difluoro-nitro-methyl)-4-ethoxy-2-trifluoromethyl-oxetane 
• 17129-03-2 4-ethoxy-1,1-difluoro-1-nitro-2-trifluoromethyl-but-3-en-2-ol 

Downstream Products

• 136547-16-5 4-(trifluoromethyl)pyrimidine 
• 136547-17-6 4-trifluoromethyl-2-mercaptopyrimidine 
• 1242530-12-6 5-ethoxy-3-hydroxy-2-phenyl-3-trifluoromethyl-pent-4-enenitrile 
• 50650-59-4 4-(trifluoromethyl)-2-pyridone 
• 134219-71-9 1-trifluoromethyl-3-(phenylamino)prop-2-en-1-one 
• 1184873-40-2 N-methylmorpholinium 3-cyano-6-trifluoromethylpyridine-2-thiolate 
• 1108192-98-8 6-benzyl-2-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 1030632-94-0 3-ethyl-6-trifluoromethyl pyridine 
• 120417-45-0 4-amino-1,1,1-trifluoro-3-buten-2-one 
• 896467-62-2 1-(4-methoxybenzyl)-4-nitro-3-[1-(3-trifluoromethyl)-pyrazolyl]pyrazole 

Related news

The interaction of 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (cas 17129-06-5) with triethyl phosphite08/15/2019

4-Ethoxy-1,1,1-trifluoro-3-buten-2-one reacts with triethyl phosphite on heating to give a [4 + 2 cycloaddition product 2,2,2-triethoxy 2,3-dihydro-3-ethoxy-5-trifluoromethyl-1,2λ5-oxaphospholene. Its hydrolysis yields, ultimately, a 2-oxo-2-hydroxy-2, 3-dihydro-3-hydroxy 5-trifluoromethyl-1,2λ...detailed

The interaction of 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (cas 17129-06-5) with C-nucleophiles — organo-magnesium and -zinc compounds08/14/2019

4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (1) reacts with phenylmagnesium bromide to give ethoxy group substitution products while the reaction of 1 with organozinc compounds gives products arising from 1,2-addition to the carbonyl group. Enone 1 reacts with electron-rich aromatic systems such as i...detailed

Study on the 1,3-dipolar cycloaddition reaction of 4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (cas 17129-06-5) with nitrile oxides08/13/2019

1,3-Dipolar cycloaddition (1,3-DC) reaction of 4-ethoxy-1,1,1-trifluoro-3-buten-2-one 1 with nitrile oxides was studied. It was found that besides its CC participating in the formation of isoxazole rings, trifluoromethyl activated CO also underwent 1,3-DC reaction with nitrile oxides to afford 1...detailed

Relevant articles and documents

2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists

A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.

Preparation method of N-(2-methoxycarbonyl vinyl)-4, 4, 4-trifluoro-3-ketone-1-buteneamine

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of N-(2-methoxycarbonyl vinyl)-4, 4, 4-trifluoro-3-ketone-1-buteneamine, and the preparation method of N-(2-methoxycarbonyl vinyl)-4, 4, 4-trifluoro-3-ketone-1-buteneamine comprises the following steps: taking trifluoroacetic acid, vinyl ethyl ether, methylsulfonyl chloride and pyridine as raw materials, firstly preparing 4-ethoxy-1, 1, 1-trifluoro-3-butene-2-ketone, carrying out ammonia ammoniation to obtain 4-amino-1, 1, 1-trifluoro-3-butene-2-ketone, then, under the action of sodium hydroxide, reacting with methyl 3-methoxyacrylate to obtain a target product N-(2-methoxycarbonyl vinyl)-4, 4, 4-trifluoro-3-ketone-1-buteneamine. The adopted raw materials are relatively cheap and easy to obtain, and the method is easy and convenient to operate, safe, feasible, high in cost performance and suitable for industrial production.

KRAS G12C Mutant protein inhibitor and pharmaceutical composition thereof Preparation method and application

The present invention provides compounds having irreversible inhibitor activity G12C mutant KRAS protein, racemates, stereoisomers, pharmaceutically acceptable salts, polymorphs or solvates thereof, the structure of which is shown in formula (I). Also provided are methods related to the preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods of modulating G12C mutant KRAS protein activity for treatment of disorders such as cancer.